CHARMAINE CORONADO: Open Payments
NPI 1144860057 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$687 in 31 payments from 9 companies in 2025. Trend: 2023 $422 · 2024 $600 · 2025 $687
Food & beverage: $687
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $237 |
| AstraZeneca Pharmaceuticals LP | 7 | $152 |
| Amgen Inc. | 4 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| PFIZER INC. | 2 | $44 |
| Novo Nordisk Inc | 2 | $36 |
| Boston Scientific Corporation | 1 | $21 |
| ABBVIE INC. | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
Products named: TRELEGY ELLIPTA, FARXIGA, OTEZLA, CAPLYTA, AIRSUPRA, ELIQUIS, Rybelsus, TheraSphere Administration Set.
Industry payments across NV — which companies pay providers there.
